STAT3 and sclerosing cholangitis: Fibroblast activation protein (FAP) depletion, increasing the vitamin A concentration, activation of vitamin D receptor, primary sclerosing cholangitis (PSC) deactivation, C-X-C motif chemokine ligand 12 (CXCL12) blocking, TGF-β inhibition, and inhibiting the Janus kinase/signal transducers and activators of transcription 3 (JAK/STAT3) pathway are a few of the strategies used in CAF's targeted therapies.